Duchenne muscular dystrophy (DMD) is treated with a combination of corticosteroids, genetic therapies, and supportive care targeting the heart, lungs, bones, and muscles. There is no cure, but treatments available today can extend the ability to walk by several years, slow muscle damage, and significantly improve quality of life compared to just a decade ago.
Corticosteroids: The Foundation of Treatment
Corticosteroids remain the first-line treatment for DMD. They slow muscle breakdown, preserve strength, and help maintain lung function. The two most commonly used are prednisone and deflazacort, and both are typically started soon after diagnosis, often between ages 2 and 5.
Deflazacort has been shown to delay loss of walking ability by roughly 1.4 to 2.5 years compared to no treatment. Prednisone and deflazacort appear to be roughly equivalent in improving motor function, though deflazacort tends to cause less weight gain while prednisone carries a lower cost. Both come with significant side effects over years of use, including weight gain, bone thinning, behavioral changes, and growth suppression. Your child’s care team will weigh these tradeoffs and may adjust dosing schedules to manage side effects while keeping the benefits.
Gene Therapy and Exon Skipping
DMD is caused by mutations in the gene that produces dystrophin, a protein muscles need to stay intact. Without it, muscle fibers break down with every contraction. Several newer therapies aim to restore at least a partial version of this protein.
Elevidys (Gene Transfer Therapy)
Elevidys is a one-time intravenous gene therapy approved for children aged 4 and older. It uses a harmless virus to deliver a shortened but functional version of the dystrophin gene directly into muscle cells. Clinical trials showed that treated patients had statistically significant improvements in motor function over two years compared to matched controls. The therapy produces a smaller-than-normal form of dystrophin, so it does not fully replace what’s missing, but it can meaningfully slow disease progression.
Exon Skipping Drugs
Exon skipping works differently. These drugs don’t replace the gene. Instead, they instruct cells to skip over the damaged section of the gene during protein production, resulting in a shorter but partially functional dystrophin protein. The catch is that each drug only works for patients with specific mutations:
- Eteplirsen (Exondys 51) targets exon 51, applicable to about 14% of patients
- Golodirsen (Vyondys 53) and viltolarsen (Viltepso) target exon 53, applicable to about 10%
- Casimersen (Amondys 45) targets exon 45, applicable to about 9%
Genetic testing is essential to determine which mutation your child has and whether any of these drugs are an option. Together, these therapies cover roughly a third of all DMD patients.
Duvyzat: A Newer Add-On Therapy
Duvyzat (givinostat) was approved in March 2024 for patients aged 6 and older. Unlike gene-targeted therapies, it works by reducing inflammation and the buildup of scar tissue and fat that replaces muscle over time. It is taken as an oral medication and is used alongside corticosteroids rather than replacing them, giving families an additional tool to slow muscle deterioration.
Heart Monitoring and Protection
Nearly all boys with DMD eventually develop heart problems because the heart muscle, like skeletal muscle, depends on dystrophin. Current guidelines recommend yearly cardiac screening starting at the time of diagnosis. These visits include an electrocardiogram and imaging, with cardiac MRI now considered the preferred method when the child is old enough to cooperate with the scan.
Doctors typically start heart-protective medications (usually drugs that reduce the workload on the heart) before symptoms appear, often by age 10. Once cardiac abnormalities are detected, screening becomes more frequent. Early and consistent monitoring is one of the most important factors in extending life expectancy, which has improved from the late teens to the late 20s or beyond with modern cardiac care.
Breathing Support
As the muscles that control breathing weaken, lung capacity gradually declines. Care teams track this using a measurement called forced vital capacity (FVC), which shows how much air someone can forcefully exhale. When FVC drops below 80% of predicted with symptoms, or below 50% without symptoms, nighttime breathing support is typically introduced.
This usually starts with a bilevel positive airway pressure (BiPAP) machine used during sleep. It helps keep the lungs fully inflated and prevents the dangerous buildup of carbon dioxide overnight. As the disease progresses, some patients need ventilation support during the day as well.
Cough assist devices become important once the muscles used for coughing weaken, since an ineffective cough makes respiratory infections much more dangerous. These devices help clear mucus from the airways mechanically, reducing the risk of pneumonia.
Physical Therapy and Stretching
Daily stretching is a core part of DMD management. As muscles weaken, the tendons and tissues around joints tighten, creating contractures that limit movement and comfort. Regular stretching of the shoulders, elbows, wrists, hips, knees, and ankles should begin early and continue through adulthood. While stretching doesn’t stop the underlying muscle loss, it maintains range of motion, reduces stiffness, decreases discomfort, and improves overall well-being.
Night splints (also called ankle-foot orthoses, or AFOs) are usually introduced near the time of diagnosis. These braces hold the ankles and feet in a stretched position for several hours overnight, helping prevent the tight heel cords that can accelerate loss of walking ability. They are not recommended during the day because they can increase fall risk and place extra demand on weakening thigh muscles.
Bone Health
Boys with DMD face a double hit to their bones: reduced weight-bearing activity from muscle weakness and the bone-thinning effects of long-term steroid use. Vertebral fractures are common and sometimes go unrecognized because they can occur without significant trauma.
Getting enough calcium and vitamin D is essential. For children aged 4 to 8, the recommended daily intake is 1,000 mg of calcium and 600 IU of vitamin D. For those aged 9 and older, calcium needs rise to 1,300 mg daily. Children on chronic steroids, those with higher body fat, darker skin, or absorption issues may need higher doses of vitamin D, which should be guided by blood level monitoring. Your care team will check bone density periodically and may add other bone-strengthening treatments if fractures occur.
Scoliosis Management
Scoliosis develops in the majority of boys with DMD, particularly after they transition to a wheelchair. Without the balancing forces of walking, the spine curves progressively. Care teams monitor the curve using X-rays and a measurement called the Cobb angle. Surgery, typically a spinal fusion, is generally recommended when the curve reaches between 20 and 50 degrees, ideally before lung function declines too far to safely tolerate the procedure. Timing matters because a severely curved spine further compresses the lungs and makes breathing support less effective.
Coordinating It All
What makes DMD care complex is that it touches nearly every body system, and interventions need to be timed and layered carefully. Most families work with a multidisciplinary team that includes a neurologist, cardiologist, pulmonologist, orthopedic surgeon, endocrinologist, physical therapist, and occupational therapist. Major academic medical centers and muscular dystrophy clinics coordinate these specialists so that visits can be combined and treatment plans stay aligned. The Muscular Dystrophy Association and Parent Project Muscular Dystrophy both maintain directories of certified care centers and can help families find comprehensive teams in their region.